Prostamax vs Vilon
Moderate Research vs Moderate Research
compatible Different organ targets; can be used in comprehensive bioregulator protocols.
Molecular Data
Prostamax Vilon
Weight 473 Da 275 Da
Half-life Not established Not established
Chain 4 amino acids 2 amino acids
Type Tetrapeptide bioregulator Dipeptide bioregulator
Key Benefits
Prostamax
01 Reduces prostate inflammation
02 Decreases prostatic swelling
03 Reduces vascular congestion (hyperemia)
04 Decreases immune cell infiltration
05 Reduces scarring in prostate tissue
06 Promotes chromatin decondensation
07 Reactivates age-repressed genes
08 Improves lymphocyte function
Vilon
01 Increases mean lifespan 20-40% in animal models
02 Suppresses tumor development
03 Stimulates thymocyte proliferation
04 Activates T-helper cells
05 Restores chromatin structure in aged lymphocytes
06 Enhances intestinal barrier function
07 Improves enzyme activity in aged tissue
08 Part of comprehensive longevity protocols
Dosing Protocols
Prostamax
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10-15 days
Vilon
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Prostamax
Generally well-tolerated
Minimal side effects reported
Vilon
Generally well-tolerated
Minimal side effects reported
Contraindications
Prostate cancer (consult oncologist)
Known hypersensitivity
Pregnancy (not applicable)
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Prostamax Vilon
Status Moderate Research Moderate Research
References 4 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.